This was consistent with previous studies; Murugan et al. found that HNSCC with TP53 mutation resulted in a higher cell cycle rate, worse pathological differentiation and more invasive clinical phenotype [45]. This evidence concerns the gene TP53 and head and neck squamous cell carcinoma.